A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database

Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged ⩽18 years in the UK. Methods: Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing pa...

Full description

Saved in:
Bibliographic Details
Published inArchives of disease in childhood Vol. 89; no. 12; pp. 1098 - 1102
Main Authors Murray, M L, de Vries, C S, Wong, I C K
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health 01.12.2004
BMJ
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Subjects
Online AccessGet full text
ISSN0003-9888
1468-2044
1468-2044
DOI10.1136/adc.2004.064956

Cover

Loading…
Abstract Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged ⩽18 years in the UK. Methods: Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified. Results: A total of 24 976 subjects received 93 091 prescriptions; 51 868 (55.7%), 38 429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged ⩽10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged ⩾15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07). Conclusions: SSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.
AbstractList Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged [= or <, slanted]18 years in the UK. Methods: Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified. Results: A total of 24 976 subjects received 93 091 prescriptions; 51 868 (55.7%), 38 429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged [= or <, slanted]10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged [= or >, slanted]15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07). Conclusions: SSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.
Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged ⩽18 years in the UK. Methods: Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified. Results: A total of 24 976 subjects received 93 091 prescriptions; 51 868 (55.7%), 38 429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged ⩽10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged ⩾15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07). Conclusions: SSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.
To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged < or =18 years in the UK. Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified. A total of 24,976 subjects received 93,091 prescriptions; 51,868 (55.7%), 38,429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged < or =10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged > or =15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07). SSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.
To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged < or =18 years in the UK.AIMSTo characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged < or =18 years in the UK.Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified.METHODSSubjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified.A total of 24,976 subjects received 93,091 prescriptions; 51,868 (55.7%), 38,429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged < or =10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged > or =15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07).RESULTSA total of 24,976 subjects received 93,091 prescriptions; 51,868 (55.7%), 38,429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged < or =10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged > or =15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07).SSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.CONCLUSIONSSSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.
Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged ⩽18 years in the UK. Methods: Subjects issued at least one ATD prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing patterns, annual prevalence, morbidity patterns, and time to discontinuation of ATD use were identified. Results: A total of 24 976 subjects received 93 091 prescriptions; 51 868 (55.7%), 38 429 (41.3%), and 2708 (2.9%) prescriptions were for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other ATDs respectively. ATD prevalence increased 1.7-fold from 1992 to 2001. TCA prevalence decreased by 30% from 3.6 to 2.5 per 1,000; SSRI prevalence increased 10 times from 0.5 to 4.6 per 1,000. In new ATD users aged ⩽10 years, the most common diagnosis associated with TCA use was nocturnal enuresis (75.1%); in those aged ⩾15 years, it was depression (45.8%). Depression was also associated with SSRI use (69.0%). For new users with depression, the median treatment durations for TCAs and SSRIs were 30 and 58 days respectively. TCA users were more likely to terminate treatment than SSRI users (TCAs v fluoxetine: 1.40, 95% CI 1.32 to 1.47; non-fluoxetine SSRIs v fluoxetine: 1.01, 95% CI 0.96 to 1.07). Conclusions: SSRIs have gained popularity for the treatment of depression compared with TCAs. TCAs are still used despite their lack of efficacy in prepubertal depression and their moderate effect in adolescents. However, >50% of subjects discontinue treatment after two months, with TCA users stopping earlier than SSRI users.
Audience Professional
Academic
Author de Vries, C S
Wong, I C K
Murray, M L
AuthorAffiliation Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London WC1N 1AX, UK. macey.murray@ulsop.ac.uk
AuthorAffiliation_xml – name: Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London WC1N 1AX, UK. macey.murray@ulsop.ac.uk
Author_xml – sequence: 1
  givenname: M L
  surname: Murray
  fullname: Murray, M L
  organization: Director and Reader in Paediatric Pharmacy, Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London and Institute of Child Health, University College London, London, UK
– sequence: 2
  givenname: C S
  surname: de Vries
  fullname: de Vries, C S
  organization: Director and Reader in Paediatric Pharmacy, Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London and Institute of Child Health, University College London, London, UK
– sequence: 3
  givenname: I C K
  surname: Wong
  fullname: Wong, I C K
  organization: Director and Reader in Paediatric Pharmacy, Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London and Institute of Child Health, University College London, London, UK
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16339645$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/15557040$$D View this record in MEDLINE/PubMed
BookMark eNqFks1v1DAQxSNURD_gzA1ZQnBA2q0d24lzQVoFWpAqivjo1XKcya4Xr73YDqL_PU53aaEHONnS_Gb83vgdFwfOOyiKpwTPCaHVqer1vMSYzXHFGl49KI4Iq8SsxIwdFEcYYzprhBCHxXGMa4xJKQR9VBwSznmNGT4q0gL1YVyiMRlrokrGOxTT2F8jPyDlkulhGyDGfI3IOKRXxvYBXK71SPXeQtQw1cZo3BKlFaBzcBCURR-D0sloQJ8gggp6hd6opDoV4XHxcFA2wpP9eVJ8PXv7pX03u7g8f98uLmYd5yLNGBl0iSnvFO4a6GsMQmGgAyaKEtzxHjgDWmHoWKlV1ZBO6UFgDYL1FYOOnhSvd3O3Y7eBfhKahcltMBsVrqVXRv5dcWYll_6HJDVp6ornAS_3A4L_PkJMcmOyX2uVAz9GWdW4EfwGfH4PXPsxuGxOElGKklBaskzNdtRSWZDGae8S_EzaWwtLkNl7eykXpKwbhjEvM__sT_23wn9_XwZe7AEVtbJDUE6beMdVlDYVm-Sd7jgdfIwBhjsEyylIMgdJTkGSuyDlDn6vQ5t0E4-8KGP_0be3aGK2dvuMCt_ysmjN5YerVtafW0Lbsys5WXy147vN-r-ifgFDyule
CODEN ADCHAK
CitedBy_id crossref_primary_10_1111_j_1365_2214_2006_00703_x
crossref_primary_10_1089_cap_2009_0040
crossref_primary_10_1136_archdischild_2017_314692
crossref_primary_10_1177_0269881106075642
crossref_primary_10_3109_13651501_2011_640939
crossref_primary_10_1111_j_1365_2206_2010_00707_x
crossref_primary_10_1007_s00787_013_0395_9
crossref_primary_10_1016_S0034_7450_13_70002_7
crossref_primary_10_1371_journal_pone_0033181
crossref_primary_10_1108_17465729200400021
crossref_primary_10_2165_11591120_000000000_00000
crossref_primary_10_1111_j_1600_0447_2006_00951_x
crossref_primary_10_1089_cap_2014_0058
crossref_primary_10_1089_cap_2015_0263
crossref_primary_10_1016_j_jad_2016_12_047
crossref_primary_10_1007_s00228_014_1676_z
crossref_primary_10_2165_00002018_200528120_00009
crossref_primary_10_1016_j_rcpeng_2018_05_003
crossref_primary_10_1111_j_1467_7717_2007_00341_x
crossref_primary_10_1007_s10578_014_0454_6
crossref_primary_10_1016_j_jad_2021_03_022
crossref_primary_10_2165_11317630_000000000_00000
crossref_primary_10_1590_1414_431x20164806
crossref_primary_10_3109_08039488_2013_804118
crossref_primary_10_1542_peds_2007_2008
crossref_primary_10_1016_j_psiq_2011_10_001
crossref_primary_10_1177_1053825913481581
crossref_primary_10_1007_s00198_015_3213_z
crossref_primary_10_1007_s40272_015_0139_z
crossref_primary_10_1016_j_rcp_2018_05_001
crossref_primary_10_1177_0883073812450319
crossref_primary_10_1007_s00431_006_0244_7
crossref_primary_10_1017_S0033291724002861
crossref_primary_10_1111_j_1469_7610_2008_01938_x
crossref_primary_10_1007_s40801_015_0049_y
crossref_primary_10_1016_j_jad_2022_08_094
crossref_primary_10_1093_eurpub_ckr137
crossref_primary_10_1186_s12887_015_0436_2
crossref_primary_10_1002_pds_1396
crossref_primary_10_1016_j_jad_2024_01_163
crossref_primary_10_1192_bjp_bp_107_045245
crossref_primary_10_1007_s00787_014_0631_y
crossref_primary_10_1097_YCO_0b013e328314b776
crossref_primary_10_1111_j_1365_2125_2009_03528_x
crossref_primary_10_1097_YIC_0000000000000216
crossref_primary_10_1186_2050_6511_15_11
crossref_primary_10_1192_bjp_187_4_304
crossref_primary_10_1542_peds_2007_3349
crossref_primary_10_1111_j_1365_2125_2008_03347_x
crossref_primary_10_18632_oncotarget_7049
crossref_primary_10_1097_WNF_0000000000000447
crossref_primary_10_1089_cap_2016_0017
crossref_primary_10_1007_s10654_009_9321_3
crossref_primary_10_1097_DBP_0000000000000058
crossref_primary_10_1089_cap_2007_0091
crossref_primary_10_1136_bmjopen_2019_031707
crossref_primary_10_1111_j_1365_2125_2005_02450_x
crossref_primary_10_1007_s40501_015_0034_9
crossref_primary_10_1089_cap_2006_16_197
crossref_primary_10_1186_1753_2000_2_26
crossref_primary_10_1002_pds_1661
crossref_primary_10_1097_01_yco_0000228762_40979_8f
crossref_primary_10_1017_S0033291716002099
crossref_primary_10_1002_pds_1027
crossref_primary_10_1016_j_chc_2006_05_006
crossref_primary_10_1111_j_1365_2125_2006_02780_x
crossref_primary_10_1016_j_jad_2021_07_096
crossref_primary_10_1007_s00228_012_1233_6
crossref_primary_10_1017_S1092852913000576
crossref_primary_10_1177_070674370805300305
crossref_primary_10_1002_pits_20426
crossref_primary_10_1016_j_jad_2023_10_055
crossref_primary_10_1136_bmjopen_2018_028201
crossref_primary_10_1016_j_jadohealth_2005_07_012
crossref_primary_10_1016_j_euroneuro_2010_11_007
crossref_primary_10_1002_phar_1387
crossref_primary_10_1016_j_psychres_2010_06_007
crossref_primary_10_1007_s00787_014_0523_1
crossref_primary_10_1007_s11469_008_9167_z
crossref_primary_10_1002_pds_1254
crossref_primary_10_1517_14656566_2012_726613
crossref_primary_10_1592_phco_31_7_623
crossref_primary_10_1111_j_1365_2214_2006_00588_x
crossref_primary_10_1002_pds_3312
crossref_primary_10_1157_13087333
crossref_primary_10_1016_j_euroneuro_2007_06_001
crossref_primary_10_1177_070674371405900204
crossref_primary_10_1007_s00787_013_0445_3
crossref_primary_10_1016_j_euroneuro_2005_06_004
crossref_primary_10_1007_s00345_021_03664_y
ClassificationCodes E121920
ContentType Journal Article
Copyright Copyright 2004 Archives of Disease in Childhood
2005 INIST-CNRS
Copyright: 2004 Copyright 2004 Archives of Disease in Childhood
Copyright_xml – notice: Copyright 2004 Archives of Disease in Childhood
– notice: 2005 INIST-CNRS
– notice: Copyright: 2004 Copyright 2004 Archives of Disease in Childhood
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
0-V
3V.
7X7
7XB
88B
88E
88I
8A4
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ALSLI
AN0
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
CJNVE
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0P
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEDU
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1136/adc.2004.064956
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Social Sciences Premium Collection
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Education Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
Education Periodicals
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Social Science Premium Collection
British Nursing Database
ProQuest Central Essentials
Biological Science Collection
ProQuest Central (subscription)
Natural Science Collection
BMJ Journals
ProQuest One
Education Collection
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Education Database
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database ProQuest
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Education
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Education
ProQuest Central Student
ProQuest Central Essentials
ProQuest AP Science
SciTech Premium Collection
ProQuest Central China
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Social Science Premium Collection
Education Collection
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Professional Education
Biological Science Database
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Social Sciences Premium Collection
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central Basic
ProQuest Education Journals
ProQuest Science Journals
British Nursing Index with Full Text
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Education Journals (Alumni Edition)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Education

MEDLINE
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2044
EndPage 1102
ExternalDocumentID PMC1719765
4213205251
A127940052
15557040
16339645
10_1136_adc_2004_064956
ark_67375_NVC_7SC13CFV_2
archdischild
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United Kingdom
Europe
United Kingdom--UK
GeographicLocations_xml – name: United Kingdom--UK
GroupedDBID ---
..I
.55
.GJ
.VT
0-V
0R~
1CY
23M
23N
2WC
354
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8A4
8AF
8F7
8FE
8FH
8FI
8FJ
8GL
8R4
8R5
AAHLL
AAKAS
AAOJX
AAQOH
AAUVZ
AAWJN
AAWTL
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABPPZ
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACNCT
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADZCM
AENEX
AEUYN
AFFNX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AIKWM
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALSLI
AN0
AOIJS
ARALO
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BCR
BENPR
BES
BHPHI
BKNYI
BLC
BLJBA
BNQBC
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
CJNVE
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
EX3
F5P
FEDTE
FYUFA
GICCO
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IER
IHR
INH
INR
IOF
IPC
ISE
ITC
K9-
KO8
KQ8
LK8
M0P
M0R
M1P
M2P
M7P
NEJ
NTWIH
NXWIF
O9-
OHT
OK1
OVD
P2P
PCD
PHGZT
PQEDU
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
SJN
TEORI
TR2
UAW
UHB
UKHRP
UYXKK
V24
VM9
W2D
W8F
WH7
WOW
X7M
YOC
YQY
YYQ
ZGI
ZXP
3V.
BSCLL
FRP
RHF
AAFWJ
AAYXX
ACQHZ
AERUA
CITATION
PHGZM
ADXHL
IQODW
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-b558t-41fc2035ba0b9ed70e8a0e3f01a310b5de54e360eb42ca691bacf80ce84d64eb3
IEDL.DBID 7X7
ISSN 0003-9888
1468-2044
IngestDate Thu Aug 21 18:22:17 EDT 2025
Thu Jul 10 19:28:23 EDT 2025
Sat Aug 23 12:55:35 EDT 2025
Tue Jun 10 19:29:32 EDT 2025
Thu Jan 02 22:00:09 EST 2025
Mon Jul 21 09:16:56 EDT 2025
Tue Jul 01 00:55:20 EDT 2025
Thu Apr 24 23:01:13 EDT 2025
Wed Oct 30 09:40:04 EDT 2024
Thu Apr 24 23:02:05 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Human
Consumption
Pediatrics
Psychotropic
Adolescent
Database
Antidepressant agent
General practice
Child
Statistical study
Public health
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b558t-41fc2035ba0b9ed70e8a0e3f01a310b5de54e360eb42ca691bacf80ce84d64eb3
Notes istex:0B8E8736E59436A1C56A02A15C1F064CC50B4A79
local:0891098
ark:/67375/NVC-7SC13CFV-2
href:archdischild-89-1098.pdf
Correspondence to:
 Mrs M L Murray
 Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, 29–39 Brunswick Square, London WC1N 1AX, UK; macey.murray@ulsop.ac.uk
PMID:15557040
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://adc.bmj.com/content/archdischild/89/12/1098.full.pdf
PMID 15557040
PQID 1828213324
PQPubID 2041043
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_1719765
proquest_miscellaneous_67098565
proquest_journals_1828213324
gale_incontextcollege_GICCO_A127940052
pubmed_primary_15557040
pascalfrancis_primary_16339645
crossref_primary_10_1136_adc_2004_064956
crossref_citationtrail_10_1136_adc_2004_064956
istex_primary_ark_67375_NVC_7SC13CFV_2
bmj_primary_10_1136_adc_2004_064956
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2004-12-01
PublicationDateYYYYMMDD 2004-12-01
PublicationDate_xml – month: 12
  year: 2004
  text: 2004-12-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Archives of disease in childhood
PublicationTitleAlternate Arch Dis Child
PublicationYear 2004
Publisher BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
BMJ
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
– name: BMJ
– name: BMJ Publishing Group Ltd
– name: BMJ Publishing Group LTD
References 11986427 - Pediatrics. 2002 May;109(5):721-7
14988209 - BMJ. 2004 Feb 28;328(7438):524-5
11437014 - J Am Acad Child Adolesc Psychiatry. 2001 Jul;40(7):762-72
11001236 - J Clin Psychopharmacol. 2000 Oct;20(5):523-30
8936916 - J Am Acad Child Adolesc Psychiatry. 1996 Nov;35(11):1491-501
15265848 - JAMA. 2004 Jul 21;292(3):338-43
11323729 - N Engl J Med. 2001 Apr 26;344(17):1279-85
15073072 - BMJ. 2004 Apr 10;328(7444):879-83
9055151 - J Dev Behav Pediatr. 1997 Feb;18(1):49-56
10697062 - JAMA. 2000 Feb 23;283(8):1025-30
11343498 - Arch Pediatr Adolesc Med. 2001 May;155(5):560-5
15169696 - Am J Psychiatry. 2004 Jun;161(6):1079-83
9134574 - Popul Trends. 1997 Spring;(87):36-40
12941675 - JAMA. 2003 Aug 27;290(8):1033-41
9842950 - JAMA. 1998 Nov 25;280(20):1752-6
3882682 - J Clin Psychiatry. 1985 Mar;46(3 Pt 2):53-8
12364842 - J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1205-15
15110490 - Lancet. 2004 Apr 24;363(9418):1341-5
References_xml – reference: 15073072 - BMJ. 2004 Apr 10;328(7444):879-83
– reference: 9055151 - J Dev Behav Pediatr. 1997 Feb;18(1):49-56
– reference: 12941675 - JAMA. 2003 Aug 27;290(8):1033-41
– reference: 9134574 - Popul Trends. 1997 Spring;(87):36-40
– reference: 10697062 - JAMA. 2000 Feb 23;283(8):1025-30
– reference: 11986427 - Pediatrics. 2002 May;109(5):721-7
– reference: 11437014 - J Am Acad Child Adolesc Psychiatry. 2001 Jul;40(7):762-72
– reference: 14988209 - BMJ. 2004 Feb 28;328(7438):524-5
– reference: 11323729 - N Engl J Med. 2001 Apr 26;344(17):1279-85
– reference: 11343498 - Arch Pediatr Adolesc Med. 2001 May;155(5):560-5
– reference: 15169696 - Am J Psychiatry. 2004 Jun;161(6):1079-83
– reference: 9842950 - JAMA. 1998 Nov 25;280(20):1752-6
– reference: 15110490 - Lancet. 2004 Apr 24;363(9418):1341-5
– reference: 11001236 - J Clin Psychopharmacol. 2000 Oct;20(5):523-30
– reference: 12364842 - J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1205-15
– reference: 15265848 - JAMA. 2004 Jul 21;292(3):338-43
– reference: 3882682 - J Clin Psychiatry. 1985 Mar;46(3 Pt 2):53-8
– reference: 8936916 - J Am Acad Child Adolesc Psychiatry. 1996 Nov;35(11):1491-501
SSID ssj0012883
Score 2.1272793
Snippet Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged ⩽18 years in the UK. Methods: Subjects issued at least...
To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged < or =18 years in the UK. Subjects issued at least one ATD...
Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged [= or <, slanted]18 years in the UK. Methods: Subjects...
To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged < or =18 years in the UK.AIMSTo characterise prescribing...
Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged ⩽18 years in the UK. Methods: Subjects issued at least...
SourceID pubmedcentral
proquest
gale
pubmed
pascalfrancis
crossref
istex
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1098
SubjectTerms Adolescent
Adolescents
Age
antidepressant
Antidepressants
Antidepressants, Tricyclic
Antidepressive Agents - therapeutic use
Anxiety Disorders
ATD
Biological and medical sciences
Child
Child, Preschool
Childhood depression
Children
Depression (Psychology)
Depression in children
Depressive Disorder - drug therapy
Dosage and administration
Drug Prescriptions - statistics & numerical data
Drug therapy
Drug Utilization - statistics & numerical data
Evaluation
Family Practice - statistics & numerical data
Female
Gender Differences
General aspects
General Practice Research Database
GPRD
hazard ratio
Health aspects
Humans
Infant
Infant, Newborn
Male
MAOI
Medical sciences
Mental depression
Mental Disorders
monoamine oxidase inhibitor
Obsessive compulsive disorder
OCD
Original
Patient outcomes
Population
Practice Patterns, Physicians' - statistics & numerical data
Practice research
prescribing trends
Prescriptions
Psychological Patterns
randomised controlled trial
RCT
Records (Forms)
selective serotonin reuptake inhibitor
Selective serotonin reuptake inhibitors
Serotonin uptake inhibitors
SSRI
Suicides & suicide attempts
Survival Analysis
TCA
Teenagers
tricyclic antidepressant
Tricyclic antidepressants
United Kingdom
Urinary incontinence
Title A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database
URI http://adc.bmj.com/content/89/12/1098.full
https://api.istex.fr/ark:/67375/NVC-7SC13CFV-2/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/15557040
https://www.proquest.com/docview/1828213324
https://www.proquest.com/docview/67098565
https://pubmed.ncbi.nlm.nih.gov/PMC1719765
Volume 89
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLbYKiFeEHcCo1gCIV6y2YkvyRMqZdWEtDIBm_pm2YkzyrZ09CLx8zkncdoVcXn2Rdbxic859pfvI-S10qV2VrkYigcXQzzOY-cUi4UvKqG9Y1XDxHQ8Vken4uNETsKF2yLAKrszsTmoy1mBd-QHkAdnCRRUiXh3_SNG1Sh8XQ0SGjukh9RlCOnSk3XBxVFJt1PMy6HUC9Q-PFUHtmz4C8U-hOQc1at33NX3rdgUTugeWvsnQibtAqxWtXIXf8pHf4dV3ohTo3vkbkgw6aD1iPvklq8fkNvH4Qn9IVkOaDlfnVNwuMsA5aENxyydVRTMPA3YWMTH0GlNu7-9oa2kN_ifKCLmzynkjzRQV9OT8McV7eB89INdWoyTj8jp6PDr8CgO0guxkzJbxoJXRcJS6SxzuS8185llPq0Yt5APOll6KXyqmHciKazKubNFlbHCZ6JUAgr0x2S3ntX-KaEcCWQSb2UCpi4ld5muhNRMFwq5w7KIvALTm-uWXMM0RUmqDGwQSmQK025QRPa7rTFFYC9HEY3Lvw94ux7w37nf4F4bpMOoEW9TtHc2Biwy_GQGPNEoHy8T6Nh4w3pCO79AYJyWZnw2NPrLkKfD0ZmBjv0td9msQKVproSMyF7nPyYcGguzcfGIvFw3w-eObzi29rPVwiDdXgZJeESetM62mVoim5pgEdFbbrjugETi2y319FtDKM41h6xUPvv3op6TOx3LJeN7ZHc5X_kXkJEtXb_57Pqk9_5wfPK531yZ_QIWZjRl
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbargRcEM8SKK0lHuKS1klsJzkgtGy72tJ2qaCtejN24pSFki37EPCn-I3MJM5uF_E49WzHsjzj8Uz8-fsIeSrjPDZaGh-KB-PDeZz6xkjmc5sVPLaGFRUT00Ff9o75m1NxukR-Nm9hEFbZxMQqUOfDDP-Rb0EenIRQUIX81cVXH1Wj8Ha1kdCo3WLP_vgGJdv45e422PdZGHZ3jjo936kK-EaIZOLzoMhCFgmjmUltHjObaGajggUaUh0jciu4jSSzhoeZlmlgdFYkLLMJzyWH2hPGXSYtDl0gELRe7_QP383uLVC7t9HoS6G4dGRCQSS3dF4xJvJNSAJS1MteNl8-LZyG7kxooX2_I0hTj8FORS2w8acM-Hcg56WTsXuL3HQpLW3XPnibLNnyDrl24C7t75JJm-aj6RkFFz934CFasdrSYUHBsAOHxkVEDh2UtHlfDm05vcQ4RRGjf0YhY6WOLJseujdetAEQ0m090Xgy3yPHV2KW-2SlHJb2AaEBUtaEVosQljoXgUnigouYxZlEtrLEI09g6dVFTeehqjIokgoMhKKcXNUG8shmYxqVOb50lO04__sHL2Yf_Hfs52hrhQQcJSJ8svovkYIV6bxV7SCMUbBehNCx8obZgHr0GaF4sVD9k46K33eCqNM9UdBxfcFd5jOQUZRKLjyy1viPcmFqrOabyiMbs2YIMHhrpEs7nI4VEvwlkPZ7ZLV2tvnQAvnbOPNIvOCGsw5IXb7YUg4-VhTmQRxAHiwe_ntSG-R67-hgX-3v9vcekRsNxyYL1sjKZDS1jyEfnJh1twkp-XDV-_4XsCJxWg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZ2kSZeEHcCY7PERbxktRM7Th8QqlqqjbEyCTb1zdiJMwojHb0I-Gv8Os5JnHZFXJ72bMeyfM6xz4k_fx8hTxKVK2sSG0LxYEM4j9uhtQkLhcsKoZxlRcXEdDRI9k_E66EcrpGfzVsYhFU2e2K1UefjDP-RtyAPTiMoqCLRKjws4rjXf3nxNUQFKbxpbeQ0ahc5dD--Qfk2fXHQA1s_jaL-q_fd_dArDIRWynQWCl5kEYulNcy2Xa6YSw1zccG4gbTHytxJ4eKEOSuizCRtbk1WpCxzqcgTAXUojLtONlUsOcaYGi6KPY4qvo1aXxvKTE8rxOOkZfKKO1HsQTrQRuXsdfvl08q56E-HTbT0d4RrmilYrKilNv6UC_8O6bx0RvZvkOs-uaWd2htvkjVX3iJbR_76_jaZdWg-mZ9RcPZzDyOiFb8tHRcUTDzyuFzE5tBRSZuX5tCW00vcUxTR-mcUclfqabPpsX_tRRsoIe2ZmcEz-g45uRKj3CUb5bh09wnlSF4TOSMjWOpccpuqQkjFVJYgb1kakMew9PqiJvbQVUEUJxoMhPKcQtcGCsheYxqdeeZ0FPA4__sHzxcf_HfsZ2hrjVQcJTp1Vv8v0rAi3be6wyOF0vUygo6VNywGNJPPCMpTUg9Ou1q96_K42z_V0HFnxV2WM0jiuJ0IGZDtxn-037CmehleAdldNMNWg_dHpnTj-VQj1V8KBUBA7tXOthxaIpObYAFRK2646IAk5qst5ehjRWbOFYeMWD7496R2yRZEu35zMDh8SK41ZJuMb5ON2WTuHkFiOLM7VQRS8uGqQ_4XynJ0Kg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+drug+utilisation+study+of+antidepressants+in+children+and+adolescents+using+the+General+Practice+Research+Database&rft.jtitle=Archives+of+disease+in+childhood&rft.au=Murray%2C+M&rft.au=de+Vries%2C+C+S&rft.au=Wong%2C+I&rft.date=2004-12-01&rft.issn=0003-9888&rft.eissn=1468-2044&rft.volume=89&rft.issue=12&rft.spage=1098&rft.epage=1102&rft_id=info:doi/10.1136%2Fadc.2004.064956&rft_id=info%3Apmid%2F15557040&rft.externalDocID=PMC1719765
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-9888&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-9888&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-9888&client=summon